NCT06785779View on ClinicalTrials.gov

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Not yet recruitingOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Hidradenitis Suppurativa (HS)
Interventions
OTHER

Secukinmab

This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY